Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVZIO vs ETHACRYNATE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema,Off-label: Adjunct in treatment of acute hypercalcemia
2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
The terminal elimination half-life of naloxone in adults is approximately 1-2 hours. In neonates, half-life may be prolonged to 3-4 hours. Clinical context: Short half-life necessitates repeated dosing or continuous infusion for sustained opioid reversal, especially with long-acting opioids.
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Primarily hepatic glucuronidation, with N-allylnoroxymorphone as the major metabolite; CYP450 system not significantly involved.
Primarily metabolized by hepatic glutathione S-transferase (GST) to a cysteine conjugate; minor metabolism via oxidation. Excreted in urine and bile.
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation, with approximately 70% excreted in urine as naloxone-3-glucuronide. About 25% is excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Approximately 30-40% bound to plasma proteins, mainly albumin.
Approximately 95% bound, primarily to albumin.
Volume of distribution is approximately 2-3 L/kg, indicating extensive distribution into tissues beyond plasma volume. Clinical meaning: High Vd suggests rapid distribution and short half-life.
0.1-0.2 L/kg (small Vd, consistent with high protein binding and limited extravascular distribution).
Intramuscular bioavailability is approximately 100% (assumed complete absorption). Oral bioavailability is <2% due to extensive first-pass metabolism; therefore, not used orally.
Oral: approximately 100% (well absorbed, no significant first-pass metabolism).
No dose adjustment required for renal impairment.
e GFR 30-59 m L/min: reduce dose by 50%; e GFR <30 m L/min: avoid use or use with extreme caution.
No dose adjustment required for hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Weight-based: <20 kg: 0.1 mg/kg IM/SC; ≥20 kg: 2 mg IM/SC; repeat every 2-3 minutes if needed.
1 mg/kg intravenously once daily; maximum 50 mg/day. Not recommended in neonates.
No specific dose adjustment; use standard adult dosing with monitoring for adverse effects due to potential comorbidities.
Start at 25 mg intravenously once daily; increase slowly due to increased risk of electrolyte disturbances and hypotension.
Risk of recurrent respiratory depression: The duration of action of naloxone is shorter than that of most opioids, so repeat doses may be necessary. Patients should be monitored until respiratory function is fully recovered.
Ethacrynic acid (ethacrynate) can cause profound diuresis with water and electrolyte depletion; close medical supervision and dose titration are required.
May precipitate acute opioid withdrawal in opioid-dependent patients; risk of incomplete response or need for repeat doses due to short half-life; not effective for non-opioid overdoses; avoid in known hypersensitivity; use caution in patients with cardiovascular disease or those taking cardiotoxic drugs.
May cause severe electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) and volume depletion,Ototoxicity, especially with rapid IV administration or in patients with renal impairment; may be irreversible,Hyperuricemia and gout,Hepatic coma can be precipitated in patients with cirrhosis or ascites,May increase risk of digoxin toxicity due to hypokalemia,Photosensitivity reaction possible
Hypersensitivity to naloxone or any component of the formulation.
Anuria,Hypersensitivity to ethacrynic acid or any component,Severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Hepatic coma or precoma
None known; naloxone is not absorbed orally due to first-pass metabolism. No dietary restrictions.
Avoid excessive intake of salt substitutes containing potassium unless advised by your doctor. Grapefruit juice may enhance diuretic effect; monitor for hypotension. Alcohol can increase diuretic effect and risk of hypotension. Caffeine may worsen electrolyte imbalance. Ensure adequate fluid intake unless fluid restriction is prescribed.
EVZIO (naloxone) is not associated with major congenital malformations; limited data in pregnancy. Immediate reversal of opioid effects may precipitate withdrawal in the fetus, potentially causing adverse outcomes such as preterm labor or fetal distress. Third trimester use may cause neonatal opioid withdrawal syndrome (NOWS) in opioid-dependent mothers if naloxone is administered.
Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, ototoxicity, and oligohydramnios in the fetus due to diuretic effect. Avoid use in pregnancy unless clearly needed.
Naloxone is unlikely to be excreted in breast milk in significant amounts due to low bioavailability. M/P ratio not established. Preterm infusion studies show minimal transfer. Consider benefits of breastfeeding against risk of maternal opioid overdose reversal.
Excreted into breast milk in low concentrations; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., electrolyte imbalance, diuresis). Weigh benefits against risks; consider alternative diuretics.
No pharmacokinetic studies in pregnancy demonstrate need for dose adjustment. Standard dosing (0.4 mg or 2 mg intranasal/IM) is used. Pregnant patients may require higher doses due to increased volume of distribution and metabolic changes, but evidence insufficient to recommend routine dose adjustment.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, specific dose adjustments for ethacrynate sodium are not established. Use lowest effective dose and monitor for hypotension and electrolyte imbalances.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into outer thigh; can be given through clothing. Repeat every 2-3 minutes if no response. Onset of action within 2-5 minutes. Duration shorter than most opioids; monitor for recurrence of respiratory depression. Not for non-opioid overdoses.
Ethacrynate sodium is a loop diuretic used for patients with sulfonamide allergy as it is not a sulfonamide derivative. Monitor for ototoxicity, especially in patients with renal impairment or when used with other ototoxic drugs. Rapid IV administration can cause severe hypotension; infuse slowly over several minutes. Hypokalemia and hypomagnesemia are common; monitor electrolytes and consider potassium-sparing diuretic or supplementation. Ethacrynic acid can cause GI bleeding; use with caution in peptic ulcer disease.
Always call 911 immediately after giving EVZIO.,Place the device against the outer thigh and press firmly; it will automatically inject.,A short, clicking sound indicates the injection has started.,Stay with the person after injection; they may become agitated due to opioid withdrawal.,Store at room temperature; check expiration date regularly.,Tell family and friends where you keep EVZIO.
Take this medication exactly as prescribed, usually once or twice daily.,You may need to urinate frequently; take your last dose of the day early to avoid nighttime urination.,Avoid alcohol and limit salt intake to help reduce fluid retention.,Report any hearing loss, ringing in the ears, or dizziness to your healthcare provider immediately.,Eat potassium-rich foods like bananas, oranges, or potatoes unless directed otherwise by your doctor.,Weigh yourself daily and report sudden weight gain or loss to your healthcare provider.,Do not take any over-the-counter medications, especially NSAIDs, without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVZIO vs ETHACRYNATE SODIUM, answered by our medical review team.
EVZIO is a Opioid Antagonist that works by Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.. ETHACRYNATE SODIUM is a Loop Diuretic that works by Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVZIO and ETHACRYNATE SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVZIO is: 2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.. The standard adult dose of ETHACRYNATE SODIUM is: 50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVZIO and ETHACRYNATE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVZIO is classified as Category C. EVZIO (naloxone) is not associated with major congenital malformations; limited data in pregnancy. Immediate reversal of opioid effects may precipitate withdrawal in the fetus, pot. ETHACRYNATE SODIUM is classified as Category C. Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, oto. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.